← Oncology Approval Tracker

FDA DECISION ·

Wyost

denosumab-bbdz · Sandoz

Biosimilar approvalBiosimilarCancer-related bone complications and giant cell tumor of bone
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Interchangeable Xgeva biosimilar for prevention of skeletal events in multiple myeloma and bone metastases from solid tumors; for adults and skeletally mature adolescents with giant cell tumor of bone when surgery is unsuitable or would cause severe morbidity; and for hypercalcemia of malignancy refractory to bisphosphonates.

LAMPGEN ANALYSIS

Why it matters

The FDA licensed an interchangeable denosumab product for cancer-related skeletal complications and other labeled oncology settings.

What research teams should watch

Avoid mixing the cancer and bone-loss product strengths; track calcium, dental assessment and the specific treatment indication.

PRIMARY RECORDS

Sources